Xiapex
PreclinicalSmall molecule
PfizerXiapex is one of 12 small molecule programs targeting Contracture. It is currently in Preclinical.
1
Indications
6
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Contracture
#DrugCompanyPhaseTrials
1Kenalog
BBausch Health Americas, Inc.
Phase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Xiaflex
GGrupo Espanol de Tumores Neuroendocrinos
Phase 2
Clostridial Collagenase Injectable
IIndiana Hand to Shoulder Center
Approved
Botulinum Toxin a
GSKPhase 2
Accolate
Alnylam PharmaceuticalsPhase 2
AA4500
Endo PharmaceuticalsPhase 3
Ketotifen Fumarate
Tanabe Pharma CorporationPhase 3
Decadron
AAspen Global Incorporated
Preclinical
XIAFLEX
UUniversity of Calgary
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Contracture4 trials
Injectable Collagenase and Percutaneous Needle Fasciotomy for Dupuytren's Contracture
Completed·—·N/A·NCT01538017·50 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Xiapex. EMBL-EBI & Wellcome Sanger Institute.
- [4]